Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients

Carlucci et al., J. Med. Microbiol., Sep 15, 2020, doi: 10.1099/jmm.0.001250 (preprint 5/8) (Peer Reviewed)
Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients

Source PDF Share Tweet

Retrospective 932 patients. Addition of Zinc to HCQ+AZ reduces mortality / transfer to hospice, ICU admission, and the need for ventilation.

Reduction in mortality or transfer to hospice adjusted odds ratio OR 0.56, p = 0.002; increase in being discharged home, adjusted OR 1.53, p = 0.008.

Carlucci et al., 5/8/2020, retrospective, peer-reviewed, 6 authors.

risk of combined death/hospice, 37.8% lower, RR 0.62, p = 0.002, treatment 411, control 521, odds ratio converted to relative risk.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 22 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit